In Brief: SangStat Sang-35
Executive Summary
SangStat Sang-35: Company receives "minor deficiency" action letter from FDA on pending application for generic cyclosporine, bioequivalent to Novartis' Neoral. FDA cited concerns about chemistry, manufacturing and labeling, SangStat said...